Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 327

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 2
Chunk 327
---
 the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.

 The Company granted options
to purchase 1,000,000 shares of Common Stock to employees with a five-year vesting period during the year end June 30, 2025 under the
2019 and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees
with a five-year vesting period under the 2019 and 2023 Plan.

 The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase 369,500 shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.

 The Company granted options
to purchase 1,850,000 shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.

During the years ended June 30,
2025 and 2024, the Company granted options to purchase 362,904 and 424,412 shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.

During the years ended June
30, 2025 and 2024, the Company granted options to purchase 0 zero and 329,729
shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the 2019 and
2023 Plan.

During the years ended June 30,
2025, and 2024, the Company granted options to purchase zero and 10,000 shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.

On November